SCHEMBL29709348

SCHEMBL29709348

CCOC(=O)N[C@H]1CCN(C2CCC3(CC2)C(=O)Nc2cc(OC)ccc23)C1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.43
MAPKAPK2 P49137 1/20 0.40
CHRM1 P11229 3/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM2B Q8NHM5 5/20 0.37
RAF1 P04049 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20073892 1.00 MAPK14 (0.43) MAPK14MAPKAPK2CHRM1MEN1POLB
SCHEMBL20073886 0.93 NQO2 (0.40) MAPK14MAPKAPK2CHRM1MEN1POLB
SCHEMBL29709316 0.91 MAPK14 (0.46) MAPK14CHRM1RAF1CYP1A2CYP2C9
SCHEMBL20073881 0.91 MAPK14 (0.46) MAPK14CHRM1RAF1CYP1A2CYP2C9
SCHEMBL23778313 0.90 MAPK14 (0.46) MAPK14KDM2BRAF1CYP1A2CYP2C9
SCHEMBL29709406 0.89 MAPK14 (0.44) MAPK14CHRM1RAF1CYP1A2CYP2C9
SCHEMBL23799235 0.89 MAPK14 (0.44) MAPK14CHRM1RAF1CYP1A2CYP2C9
SCHEMBL20073882 0.89 MAPK14 (0.44) MAPK14CHRM1RAF1CYP1A2CYP2C9
SCHEMBL20073879 0.87 CHRM1 (0.45) MAPK14CHRM1KDM4EALDH1A1
SCHEMBL20073883 0.87 CHRM1 (0.45) MAPK14CHRM1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-12-05 US disclosed
US-20220213034-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213034-A1 SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 MAPK14 4186/4885MAPKAPK2 3945/4885CHRM1 1/4885
US-11834407-B2 Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists CHRM1, CHRM2, CHRM4 MAPK14 4186/4885MAPKAPK2 3945/4885CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.